Markets

Insider Trading

Hedge Funds

Retirement

Opinion

20 States with the Highest Cancer Rates

In this article, we will be taking a look ta the 20 states with the highest cancer rates. If you do not want to learn about the global cancer market, head straight to the 5 States with the Highest Cancer Rates.

States with the highest cancer rates like Florida, Texas, and New York, among others, represent a critical aspect of public health analysis in the United States. Understanding the geographical distribution of cancer incidence is vital for targeting prevention efforts, allocating resources, and providing effective healthcare interventions. By examining the prevalence of cancer across different states, researchers and policymakers can identify trends, risk factors, and disparities, ultimately contributing to the development of targeted strategies to mitigate the burden of this disease on affected communities. 

Global and US Cancer Statistics and Market Insights 

In 2020, the global burden of cancer reached an estimated 18.1 million cases worldwide, with common types including breast, lung, colorectal, prostate, stomach, liver, and cervix uteri cancers among others. The International Agency for Research on Cancer (IARC) projected a continued rise in new cancer cases globally, with an anticipated 47% increase from 2020 to 2040. 

In the United States alone, there were 1,603,844 new reported cancer cases and 602,347 cancer-related deaths in 2020, with incidence and mortality rates of 403 and 144 per 100,000 people, respectively. Notably, advancements in oncology treatments have contributed to a significant decline in cancer deaths by approximately 29% since 1991. 

The financial landscape of the global oncology market reflects substantial growth, with a valuation of US$203.42 billion in 2022 and a projected value exceeding US$470.61 billion by 2032, exhibiting a notable compound annual growth rate (CAGR) of 8.8%. North America and Europe are pivotal regions propelling market expansion, driven by technological innovations in diagnostics and the increasing prevalence of cancer cases. Major market players are prioritizing research and development initiatives through strategic collaborations and investments to enhance their market presence. 

While advancements in oncology research offer promise for improving patient outcomes worldwide, the escalating burden of cancer emphasizes the urgent need for sustained efforts in prevention, early detection, and the development of innovative treatments to effectively address this significant public health challenge. 

The landscape of oncology in Europe shines with promise, propelled by advancements in cancer diagnostics and a rising incidence of cancer cases. In 2020 alone, Europe saw approximately 2.7 million new cancer diagnoses and 1.3 million cancer-related deaths, setting the stage for the region to emerge as a pivotal market for oncology in the coming years. 

Key Players, Market Dynamics, and Innovations Driving Cancer Treatment

The global surge in cancer cases finds roots in various factors, including escalated consumption of alcohol and tobacco. Projections from the International Agency for Research on Cancer (IARC) indicate a significant uptick in new cancer cases globally from 2020 to 2040. However, the journey through cancer treatment, particularly chemotherapy, often leaves patients grappling with long-term repercussions on their organs and healthy cells, thereby influencing market dynamics. 

The financial burden of cancer care is substantial, with patients facing median annual costs ranging from $1,730 to $4,727, exceeding those of non-cancer patients by $976 to $1,170. Between 22% and 64% of cancer patients experience distress over mounting medical bills. This escalation in costs particularly burdens low-income and uninsured individuals. Globally, men experienced a 19% higher incidence rate of all cancers in 2020 compared to women, although rates varied across regions. Asia, home to over half of the world’s population, accounted for half of all cancer cases, while Europe, with only 10% of the global population, reported 23% of cases, and North America, representing 5% of the population, reported 21% of cases. 

Merck & Co., Inc. (NYSE:MRK) led by Jannie Oosthuizen, is a key player in the global oncology market with Keytruda, a leading cancer drug. Keytruda achieved $17.2 billion in sales in 2021, with plans to reach 2 million patients by 2024. Merck & Co., Inc. (NYSE:MRK) focuses on early-stage cancers, aiming for 25% revenue from this area by 2025. They explore new tumor types, therapies, and formulations, including under-the-skin versions of Keytruda. Digital marketing enhances commercial execution. Merck & Co., Inc. (NYSE:MRK) anticipates growth through innovative combinations and formulations, that align with customer needs. Strong financial performance, driven by Keytruda and Gardasil, led to record-high share prices and better-than-expected earnings per share. Merck & Co., Inc. (NYSE:MRK) invested $30 billion in R&D in 2023.

Bristol-Myers Squibb Company (NYSE:BMY) is a leading biopharmaceutical company focused on innovative medicines, particularly in cancer treatment. Key products like Keytruda, Revlimid, and Imbruvica contribute significantly to global oncology revenues. Bristol-Myers Squibb Company (NYSE:BMY)’s recent FDA approval of repotrectinib (Augtyro) for non-small cell lung cancer strengthens their position in the market. Strategic focus includes R&D acceleration and product launches, balancing profit and loss discipline amid upcoming patent expirations.  Financially,Bristol-Myers Squibb Company (NYSE:BMY)’s fourth-quarter revenues reached $11.5 billion, showcasing strength in key products like Eliquis and Opdivo. 

A surgeon wearing a medical mask, examining a cancer patient in a surgical facility.

Our Methodology 

For our methodology, we have ranked the states with the highest cancer rates based on total cancer deaths in 2021. We’ve assumed that a high mortality rate is correlated with propoetionately high disease rate. For the accuracy of data, we relied on the Beckers Hospital Review.

Here is our list of the 20 states with the highest cancer rates.

20. South Carolina  

Total Cancer Deaths: 10,593 

South Carolina faces high rates of lung and breast cancer, with disparities in screening and survival, particularly affecting black women. Efforts focus on increasing screenings in high-risk regions like the Pee Dee area. Treatment costs vary, with access crucial, especially considering a median household income of $58,234 and a 19.4% uninsured rate for those at or below 138% of poverty. Medicaid covers lung cancer screenings without copays, but financial constraints and lack of insurance hinder access to timely care, emphasizing the need for enhanced early detection efforts. 

19. Wisconsin 

Total Cancer Deaths: 11,336 

Wisconsin stands among the states with the highest cancer rates, notably lung cancer, with significant treatment expenses including surgery, chemotherapy, and radiation therapy. Challenges include out-of-pocket costs and insurance coverage. Other prevalent cancers include breast, prostate, colorectal, and skin cancers. The state’s 5-year survival rate for lung cancer is 27.4%, slightly higher than the national average. While there’s been a 16% improvement in new cases over five years, 17.4% of cases don’t receive treatment. Surgical treatment rates for lung cancer are higher in Wisconsin at 21.9%. 

18. Massachusetts 

Total Cancer Deaths: 12,461 

Massachusetts grapples with high cancer rates and significant treatment expenses, ranging from millions to billions annually. Medicare, private insurance, and Medicaid share the financial burden. Prominent cancers include breast, colorectal, lung, prostate cancers, and non-Hodgkin lymphomas, incurring substantial medical service and prescription drug costs. Breast cancer is particularly associated with high medical service costs, while lung cancer significantly impacts oral prescription drug expenses. 

17. Arizona  

Total Cancer Deaths: 12,813 

Arizona stands among the states with highest cancer deaths, with an average of 34,274 new cases diagnosed annually and 12,194 deaths yearly. White non-Hispanics have the highest diagnosis rates, while Asian/Pacific Islanders have the lowest. The overall cancer incidence has decreased by 11%. Lung cancer is a leading cause of death, although Arizona’s new case rate of 42.0 per 100,000 is lower than the national average. The state ranks 17th for lung cancer rates, showing a 20% improvement in survival rates over five years, but only 26.5% of cases are detected early. 

16. Missouri  

Total Cancer Deaths: 13,153 

Missouri contends with high cancer rates, impacting residents significantly. Lung, breast, prostate, colorectal, skin, and pancreatic cancers are prevalent. Financial assistance programs and insurance coverage play crucial roles in managing treatment costs. The financial burden includes direct medical costs, lost productivity, and non-medical expenses. Access to affordable healthcare and community resources is vital for addressing financial challenges related to cancer care in Missouri. 

15. Washington 

Total Cancer Deaths: 13,547 

Washington State exhibits varying cancer incidence rates across different counties, with King County reporting 44.6 cases per 100,000 population and Whitman County reporting 25.4 cases per 100,000 population. Cancer treatment expenses in Washington are substantial, covering medical procedures, medications, hospital stays, and supportive care services. Lung cancer and breast cancer are prevalent, with lung cancer having a rate of 49.7 new cases per 100,000 population and approximately one in eight women developing breast cancer during their lifetime.  

14. Indiana  

Total Cancer Deaths: 13,983 

Indiana has higher cancer incidence and mortality rates compared to the national average, with a 14% higher incidence rate among females and a 24% higher mortality rate among males, making Indiana stand among the states with the highest cancer rates. The state spent $11.12 billion on indirect cancer-related costs in a year, with $2.76 billion projected for direct costs in 2023. Breast and prostate cancers are the most common types among females and males, respectively, while lung cancer causes the highest number of cancer-related deaths annually. Tobacco use contributes to about 30% of cancer deaths, and overweight/obesity is linked to around 40% of diagnosed cancers, underscoring the importance of healthy lifestyle choices. 

13. Tennessee 

Total Cancer Deaths: 14,481 

Tennessee stands among the states with high cancer deaths. Notable incidence rates include breast, bladder, brain, and cervix cancers. Lung cancer mortality rates are concerning, resulting in the loss of around 577,203 years of potential life over five years. US cancer care costs reached $124.6 billion in 2010, projected to hit $157.8 billion by 2020, with breast cancer-bearing high costs. Poverty rates are higher, income levels lower than national averages, with education levels slightly below. 

12. New Jersey 

Total Cancer Deaths: 15,481 

New Jersey faces significant challenges with higher cancer rates, particularly in lung, prostate, female breast, and colorectal cancers. Lung cancer poses a substantial health challenge due to its high mortality rate. Prostate cancer affects many individuals, presenting challenges in diagnosis and treatment. Colorectal cancer screening is crucial for better treatment outcomes. 

11. Virginia 

Total Cancer Deaths: 15,724 

Virginia has high cancer rates, notably in lung cancer. The state’s new lung cancer cases rate is 52.4 per 100,000 population, slightly lower than the national average. Surgical treatment for lung cancer cases in Virginia stands at 20.3%, with a 28% decrease in cases receiving no treatment over five years. Disparities exist, with black individuals facing disparities in incidence and treatment outcomes compared to white individuals, while Latino individuals have lower rates of new lung cancer cases compared to both national and white individuals in Virginia. 

10. Georgia  

Total Cancer Deaths: 18,136 

Georgia has higher lung cancer rates compared to the national average, with 58.2 new cases per 100,000 population. The state ranks 29th for new lung cancer cases, with a five-year survival rate of 23.8%, lower than the national rate. Only 24.8% of lung cancer cases in Georgia are detected early. Surgical treatment for lung cancer is relatively low, with 18.4% undergoing surgery, and 22.1% of cases receiving no treatment. Screening rates for high-risk individuals are also below the national average, with only 3.8% being screened. 

9. North Carolina  

Total Cancer Deaths: 20,229 

North Carolina ranks ninth in cancer deaths nationwide, with around 20,000 deaths annually. The top five causes of cancer deaths in the state are lung/bronchus, female breast, prostate, colon/rectum, and pancreatic cancer, requiring targeted prevention efforts. Financially, cancer care places a substantial burden on individuals and families, with access to affordable healthcare and insurance coverage being crucial for managing costs. 

8. Michigan  

Total Cancer Deaths: 21,211 

Michigan has higher lung cancer rates than the national average, with a rate of 60.0 new cases per 100,000 population. Surgical treatment is below the national average at 19.0%, with an increasing number of cases not receiving any treatment. Medicaid now covers lung cancer screening in Michigan. Indigenous Peoples face disparities in lung cancer diagnosis and treatment. Efforts to enhance screening have resulted in a rate of 7.1%, exceeding the national average. 

7. Illinois 

Total Cancer Deaths: 23,609 

Illinois faces a significant cancer burden, with 780,990 residents dying from cancer between 1986 and 2017. The Illinois State Cancer Registry tracks various cancers, including priority ones like breast, cervical, colorectal, lung, prostate, and skin cancers, as well as common cancers diagnosed at late stages. Invasive cancer cases reported to the registry total 1,891,426. In 2017, Black males had the highest overall age-adjusted invasive cancer incidence rates. Breast cancer is the most commonly diagnosed cancer among females in Illinois.  

6. Ohio  

Total Cancer Deaths: 25,077 

Ohio stands sixth among the states with the highest cancer rates, notably in lung cancer, with a rate of 65.1 new cases per 100,000 population. Disparities exist among racial and ethnic groups, with Black individuals experiencing higher rates. Medicaid covers lung cancer screening but requires prior authorization, potentially affecting timely care. The state grapples with other cancers as well, reflected in overall high age-adjusted cancer incidence rates.  

Click to see and continue reading the 5 States with the Highest Cancer Rates.

Suggested Articles:

Disclosure. None: The 20 States with the Highest Cancer Rates is originally published on Insider Monkey.

AI Fire Sale: Insider Monkey’s #1 AI Stock Pick Is On A Steep Discount

Artificial intelligence is the greatest investment opportunity of our lifetime. The time to invest in groundbreaking AI is now, and this stock is a steal!

The whispers are turning into roars.

Artificial intelligence isn’t science fiction anymore.

It’s the revolution reshaping every industry on the planet.

From driverless cars to medical breakthroughs, AI is on the cusp of a global explosion, and savvy investors stand to reap the rewards.

Here’s why this is the prime moment to jump on the AI bandwagon:

Exponential Growth on the Horizon: Forget linear growth – AI is poised for a hockey stick trajectory.

Imagine every sector, from healthcare to finance, infused with superhuman intelligence.

We’re talking disease prediction, hyper-personalized marketing, and automated logistics that streamline everything.

This isn’t a maybe – it’s an inevitability.

Early investors will be the ones positioned to ride the wave of this technological tsunami.

Ground Floor Opportunity: Remember the early days of the internet?

Those who saw the potential of tech giants back then are sitting pretty today.

AI is at a similar inflection point.

We’re not talking about established players – we’re talking about nimble startups with groundbreaking ideas and the potential to become the next Google or Amazon.

This is your chance to get in before the rockets take off!

Disruption is the New Name of the Game: Let’s face it, complacency breeds stagnation.

AI is the ultimate disruptor, and it’s shaking the foundations of traditional industries.

The companies that embrace AI will thrive, while the dinosaurs clinging to outdated methods will be left in the dust.

As an investor, you want to be on the side of the winners, and AI is the winning ticket.

The Talent Pool is Overflowing: The world’s brightest minds are flocking to AI.

From computer scientists to mathematicians, the next generation of innovators is pouring its energy into this field.

This influx of talent guarantees a constant stream of groundbreaking ideas and rapid advancements.

By investing in AI, you’re essentially backing the future.

The future is powered by artificial intelligence, and the time to invest is NOW.

Don’t be a spectator in this technological revolution.

Dive into the AI gold rush and watch your portfolio soar alongside the brightest minds of our generation.

This isn’t just about making money – it’s about being part of the future.

So, buckle up and get ready for the ride of your investment life!

Act Now and Unlock a Potential 10,000% Return: This AI Stock is a Diamond in the Rough (But Our Help is Key!)

The AI revolution is upon us, and savvy investors stand to make a fortune.

But with so many choices, how do you find the hidden gem – the company poised for explosive growth?

That’s where our expertise comes in.

We’ve got the answer, but there’s a twist…

Imagine an AI company so groundbreaking, so far ahead of the curve, that even if its stock price quadrupled today, it would still be considered ridiculously cheap.

That’s the potential you’re looking at. This isn’t just about a decent return – we’re talking about a 10,000% gain over the next decade!

Our research team has identified a hidden gem – an AI company with cutting-edge technology, massive potential, and a current stock price that screams opportunity.

This company boasts the most advanced technology in the AI sector, putting them leagues ahead of competitors.

It’s like having a race car on a go-kart track.

They have a strong possibility of cornering entire markets, becoming the undisputed leader in their field.

Here’s the catch (it’s a good one): To uncover this sleeping giant, you’ll need our exclusive intel.

We want to make sure none of our valued readers miss out on this groundbreaking opportunity!

That’s why we’re slashing the price of our Premium Readership Newsletter by a whopping 70%.

For a ridiculously low price of just $29, you can unlock a year’s worth of in-depth investment research and exclusive insights – that’s less than a single restaurant meal!

Here’s why this is a deal you can’t afford to pass up:

• Access to our Detailed Report on this Game-Changing AI Stock: Our in-depth report dives deep into our #1 AI stock’s groundbreaking technology and massive growth potential.

• 11 New Issues of Our Premium Readership Newsletter: You will also receive 11 new issues and at least one new stock pick per month from our monthly newsletter’s portfolio over the next 12 months. These stocks are handpicked by our research director, Dr. Inan Dogan.

• One free upcoming issue of our 70+ page Quarterly Newsletter: A value of $149

• Bonus Reports: Premium access to members-only fund manager video interviews

• Ad-Free Browsing: Enjoy a year of investment research free from distracting banner and pop-up ads, allowing you to focus on uncovering the next big opportunity.

• 30-Day Money-Back Guarantee:  If you’re not absolutely satisfied with our service, we’ll provide a full refund within 30 days, no questions asked.

 

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

1. Head over to our website and subscribe to our Premium Readership Newsletter for just $29.

2. Enjoy a year of ad-free browsing, exclusive access to our in-depth report on the revolutionary AI company, and the upcoming issues of our Premium Readership Newsletter over the next 12 months.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!


No worries about auto-renewals! Our 30-Day Money-Back Guarantee applies whether you’re joining us for the first time or renewing your subscription a year later!

A New Dawn is Coming to U.S. Stocks

I work for one of the largest independent financial publishers in the world – representing over 1 million people in 148 countries.

We’re independently funding today’s broadcast to address something on the mind of every investor in America right now…

Should I put my money in Artificial Intelligence?

Here to answer that for us… and give away his No. 1 free AI recommendation… is 50-year Wall Street titan, Marc Chaikin.

Marc’s been a trader, stockbroker, and analyst. He was the head of the options department at a major brokerage firm and is a sought-after expert for CNBC, Fox Business, Barron’s, and Yahoo! Finance…

But what Marc’s most known for is his award-winning stock-rating system. Which determines whether a stock could shoot sky-high in the next three to six months… or come crashing down.

That’s why Marc’s work appears in every Bloomberg and Reuters terminal on the planet…

And is still used by hundreds of banks, hedge funds, and brokerages to track the billions of dollars flowing in and out of stocks each day.

He’s used this system to survive nine bear markets… create three new indices for the Nasdaq… and even predict the brutal bear market of 2022, 90 days in advance.

Click to continue reading…